Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in severe autoimmune encephalitis
NCT03993262Phase 2Recruiting
- Sponsor
- Universitätsklinikum Jena
- Start
- May 2020
- Primary completion
- Sep 2026
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in Autoimmune Encephalitis (AE), sponsored by Universitätsklinikum Jena. Started May 2020; status: recruiting.
02
Drugs
bortezomib
03
Conditions
Autoimmune Encephalitis (AE)
Beyond the preview
Go deeper on NCT03993262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03993262.